AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
LONDON, February 23, 2009 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated when compared with placebo.
AstraZeneca will work with MAP Pharmaceuticals to conduct further analyses of these data to determine appropriate next steps for the program.
AstraZeneca and MAP Pharmaceuticals have a collaboration agreement to develop and commercialize UDB.
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com
CONTACT: Media Enquiries US: Emily Denney, +1-302-885-3451, Cell,+1-302-897-4953, Media Enquiries UK: Neil McCrae, +44 207 304 5045 (24hours), Chris Sampson, +44 20 7304 5130 (24 hours), Sarah Lindgreen, +44 207304 5033 (24 hours), Investor Enquiries UK: Jonathan Hunt +44 207 3045087, Cell, +44 7775 704032, Karl Hard +44 207 304 5322, Cell, +44 7789654364; Investor Enquiries US: Ed Seage, +1-302-886-4065, Cell,+1-302-373-1361, Jorgen Winroth, +1-212-579-0506, or Cell, +1-917-612-4043,all of AstraZeneca
Ticker Symbol: (NYSE:AZN)
Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: February 2009